

FIGURE 1: Serological identification system for autoantigens using a retroviral vector and flow cytometry (SARF). (a) Generation of human umbilical vein endothelial cell (HUVEC) cDNA-expressing cells. (b) Sorting of cells expressing cell-surface autoantigens.

FITC signals were sorted by flow cytometry (Figure 2(b)). After the 4th sorting, cells bound to X10-3 IgG were markedly increased (Figure 2(c), left), and the C5 clone was established from the X10-3 IgG-binding cell population by the limiting dilution method (Figure 2(c), right). Microarray analysis revealed that the signal of ICAM-1 was significantly increased ( $2^{6.16}$ -fold), and we confirmed that the ICAM-1 cDNA was inserted into the genomic DNA of X10-3-C5 clone (Figure 2(d)). We also confirmed the expression of ICAM-1 on the X10-3-C5 clone (Figure 2(e)). Next, we generated an expression vector for ICAM-1, which was transfected into YB2/0 cells. X10-3 IgG showed significant binding activity to 7-AAD-negative ICAM-1-expressing YB2/0 cells (Figure 2(f)), indicating that X10-3 IgG has anti-ICAM-1 activity. Thus, the membrane protein ICAM-1 was identified as a novel autoantigen of AECA in RA. ICAM-1 is an immunoglobulin (Ig)-like cell adhesion molecule expressed by several cell types, including leukocytes and ECs. ICAM-1 plays an important role in both innate and adaptive immune responses. It is involved in the transendothelial migration of leukocytes to sites of inflammation, as well as in interactions between antigen presenting cells (APC) and T cells (immunological synapse formation) [62].

ICAM-1 was also confirmed to transduce signals “outside in” [63, 64]. The cross-linking of ICAM-1 with monoclonal antibodies was reported to activate the mitogen-activated protein kinase (MAPK) kinases ERK-1/2 and/or JNK [65–67]. The activation of ERK-1 lead to AP-1 activation [66], the ERK-dependent production and secretion of IL-8 and RANTES [67], and upregulation of VCAM-1 on the cell surface [66, 68]. ICAM-1 cross-linking can also upregulate tissue factor production [69] and proinflammatory cytokines, including IL-1 [70]. Lawson et al. reported production of anti-ICAM-1 IgM after cardiac transplantation, and the antibody induced robust activation of the ERK-2 MAPK pathway [71]. The use of anti-ICAM-1 antibody was examined for the treatment of RA, but the second course of therapy was associated with adverse effects suggestive of immune complex formation [72]. Identification of anti-ICAM-1 antibody in a patient with RA suggested that this autoantibody may exhibit such pathogenic roles.

5.3. *Pk (Gb3/CD77)*. Using serum from an SLE patient who showed hemolytic anemia, SARF revealed that cDNA inserted into the cloned cells that were sorted with this AECA-IgG was alpha 1,4-galactosyltransferase (A4GALT).




FIGURE 2: Identification of intercellular adhesion molecule 1 (ICAM-1) as a target antigen of anti-endothelial cell antibodies (AECAs). (a) Nonpermeabilized HUVECs were stained with 0.5 mg/mL of IgG of control or X10-3 from a patient with rheumatoid arthritis followed by secondary antibody and analyzed by flow cytometry. (b) HUVEC cDNA-expressing cells were stained with 0.5 mg/mL of X10-3 IgG followed by secondary antibody, and cells in the positive fraction were sorted (black box). (c) Unsorted and 4th sorted cells (left) and unsorted and cloned cells from 4th sorted cells, C5 (right), were stained with 0.5 mg/mL of X10-3 IgG followed by secondary antibody and analyzed by flow cytometry. (d) ICAM-1 cDNA fragments inserted into the genomic DNA of C5 were amplified, and PCR products were electrophoresed on an 0.8% agarose gel. (e) Unsorted and C5 were stained with isotype control or anti-ICAM-1 antibody, followed by secondary antibody and analyzed by flow cytometry. (f) Expression vector, empty-IRES-GFP, or ICAM-1-IRES-GFP were transfected into YB 2/0 cells, and these cells were stained with 0.5 mg/mL of control IgG or X10-3 IgG, followed by secondary antibody and analyzed by flow cytometry.

This AECA showed significant binding activity to 7-AAD-negative A4GALT-overexpressing YB2/0 cells. The A4GALT locus encodes a glycosyltransferase that synthesizes the terminal Gal $\alpha$ 1-4Gal of Pk (Gb3/CD77) glycosphingolipid [73, 74]. This means that synthesis of the terminal Gal $\alpha$ 1-4Gal is needed for the binding of this AECA-IgG.

Gb3 is the Pk blood group antigen and has been designated CD77 [74]. Monoclonal antibodies against Pk (Gb3/CD77) are used as markers for Burkitt's B-cell lymphoma and are able to initiate apoptosis [75]. Pk (Gb3/CD77) plays a direct role in the entry of Shiga toxin into the cell [76], and the presence of Pk (Gb3/CD77) in the ECs of the kidney accounts for the development of hemolytic uremic syndrome during bacterial infection with *Shigella* species that produce verotoxin [77]. The anti-Pk (Gb3/CD77) antibody was reported to cause acute intravascular hemolytic transfusion reactions and recurrent spontaneous abortions due to damage to the placenta [73, 78]. These data suggested that Pk (Gb3/CD77) is one of the target antigens of AECAs in SLE patients manifesting hemolytic anemia, and that anti-Pk (Gb3/CD77) antibody may exhibit some pathogenic roles.

Identification of A4GALT indicated the usefulness of SARF, which can be used to identify genes that encode not only the membrane protein itself, but also the transferase(s) responsible for modifying the membrane protein.

As described above, this system is very useful for identification of cell-surface autoantigens. Although this system seems to present difficulties in sorting cells at very low frequency, we could isolate and clone autoantigen-expressing cells by repeated sorting.

As AECAs are a heterogeneous group of autoantibodies that target ECs, it is predicted that there are different autoantigens. Thus, it is important to determine the clinical significance and potential pathogenicity of identified autoantibodies. If an autoantibody is specific for a disease or pathophysiology, it could be used as a marker for diagnosis or classification according to the underlying pathophysiology. At the same time, the pathogenic potential of the autoantibody should also be examined. Along with *in vitro* studies mentioned previously, experimental animal models of identified autoantibody should be constructed to determine the pathogenetic reactions *in vivo*.

## 6. Summary

AECAs are considered to be critical, especially for vascular lesions in collagen diseases, but most are directed against molecules localized within the cell and not expressed on the cell surface. In addition to conventional immunoprecipitation and WB, proteomics and expression library analyses have been performed to identify the targets for AECAs with some success. SARF was developed to identify autoantigens expressed on the EC surface with greater sensitivity. Using SARF, we successfully identified three different membrane proteins as targets for AECAs: FLRT2 from patients with SLE, ICAM-1 from a patient with RA, and Pk (Gb3/CD77) from an SLE patient with hemolytic anemia. Using this technology, it may be possible to determine cell-surface autoantigens of AECAs and achieve a comprehensive understanding of

AECA-mediated vascular injury. Furthermore, SARF can be used when autoantibodies against cell-surface molecules are considered to take part in autoimmune diseases. The identification of such pathogenic autoantibodies may enable the development of more specific intervention strategies in autoimmune diseases.

## Conflict of Interests

The authors declare that they have no conflict of interests.

## Acknowledgments

The authors thank the staff of the Department of Hematology and Rheumatology, Tohoku University, for help and discussion. This work was supported in part by Network Medicine Global-COE Program from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and Biomedical Research Core of Tohoku University Graduate School of Medicine.

## References


- [1] V. Racanelli, M. Prete, G. Musaraj, F. Dammacco, and F. Perosa, "Autoantibodies to intracellular antigens: generation and pathogenetic role," *Autoimmunity Reviews*, vol. 10, no. 8, pp. 503–508, 2011.
- [2] A. Lleo, P. Invernizzi, B. Gao, M. Podda, and M. E. Gershwin, "Definition of human autoimmunity—autoantibodies versus autoimmune disease," *Autoimmunity Reviews*, vol. 9, no. 5, pp. A259–A266, 2010.
- [3] A. Davidson and B. Diamond, "Autoimmune diseases," *The New England Journal of Medicine*, vol. 345, no. 5, pp. 340–350, 2001.
- [4] Y. Naparstek and P. H. Plotz, "The role of autoantibodies in autoimmune disease," *Annual Review of Immunology*, vol. 11, pp. 79–104, 1993.
- [5] O. Bloom, K. F. Cheng, M. He et al., "Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 25, pp. 10255–10259, 2011.
- [6] K. J. Lindqvist and C. K. Osterland, "Human antibodies to vascular endothelium," *Clinical & Experimental Immunology*, vol. 9, no. 6, pp. 753–760, 1971.
- [7] P. Guilpain and L. Mouthon, "Antiendothelial cells autoantibodies in vasculitis-associated systemic diseases," *Clinical Reviews in Allergy and Immunology*, vol. 35, no. 1-2, pp. 59–65, 2008.
- [8] P. Youinou, "New target antigens for antiendothelial cell antibodies," *Immunobiology*, vol. 210, no. 10, pp. 789–797, 2005.
- [9] T. Shirai, H. Fujii, M. Ono et al., "A novel autoantibody against fibronectin leucine-rich transmembrane protein 2 expressed on the endothelial cell surface identified by retroviral vector system in systemic lupus erythematosus," *Arthritis Research & Therapy*, vol. 14, no. 4, article R157, 2012.
- [10] E. Romas, B. Paspaliaris, A. J. d'Apice, and P. R. Elliott, "Autoantibodies to neutrophil cytoplasmic (ANCA) and endothelial cell surface antigens (AECA) in chronic inflammatory bowel disease," *Australian and New Zealand Journal of Medicine*, vol. 22, no. 6, pp. 652–659, 1992.

- [11] A. G. Wangel, S. Kontiainen, L. Melamies, and T. Weber, "Hypothyroidism and anti-endothelial cell antibodies," *Acta Pathologica, Microbiologica, et Immunologica Scandinavica*, vol. 101, no. 1, pp. 91–94, 1993.
- [12] H. Gur, G. Shen, M. Stjtita et al., "Autoantibody profile of primary sclerosing cholangitis," *Pathobiology*, vol. 63, no. 2, pp. 76–82, 1995.
- [13] C. Edelsten and D. P. D'Cruz, "Antiendothelial cell antibodies (AECA) in patients with uveoretinitis," *Clinical Reviews in Allergy and Immunology*, vol. 15, no. 1, pp. 41–52, 1997.
- [14] M. Toyoda, K. Galfayan, O. A. Galera, A. Petrosian, L. S. C. Czer, and S. C. Jordan, "Cytomegalovirus infection induces anti-endothelial cell antibodies in cardiac and renal allograft recipients," *Transplant Immunology*, vol. 5, no. 2, pp. 104–111, 1997.
- [15] S. Praprotnik, M. Blank, Y. Levy et al., "Anti-endothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells," *International Immunology*, vol. 13, no. 2, pp. 203–210, 2001.
- [16] D. P. Papadopoulos, T. K. Makris, U. Papazachou, M. Daskalaki, E. Sanidas, and V. E. Votteas, "Antiendothelial cell antibody levels in patients with masked hypertension," *International Journal of Cardiology*, vol. 130, no. 3, pp. 405–408, 2008.
- [17] T. Matsui, N. Inui, T. Suda, and K. Chida, "Anti-endothelial cell antibodies in patients with interstitial lung diseases," *Respiratory Medicine*, vol. 102, no. 1, pp. 128–133, 2008.
- [18] M. Karayama, N. Inui, T. Suda, Y. Nakamura, H. Nakamura, and K. Chida, "Antiendothelial cell antibodies in patients with COPD," *Chest*, vol. 138, no. 6, pp. 1303–1308, 2010.
- [19] E. Elsheikh, C. Sylvén, and L. Henareh, "Anti-endothelial cell antibodies are increased in patients with previous myocardial infarction," *Scandinavian Cardiovascular Journal*, vol. 44, no. 5, pp. 255–259, 2010.
- [20] C. M. Magro, J. C. Poe, M. Lubow, and J. O. Susac, "Susac syndrome: an organ-specific autoimmune endotheliopathy syndrome associated with anti-endothelial cell antibodies," *American Journal of Clinical Pathology*, vol. 136, no. 6, pp. 903–912, 2011.
- [21] K. Lewandowska, M. Ciurzynski, E. Gorska et al., "Antiendothelial cells antibodies in patients with systemic sclerosis in relation to pulmonary hypertension and lung fibrosis," *Advances in Experimental Medicine and Biology*, vol. 756, pp. 147–153, 2013.
- [22] C. Mihai and J. W. C. Tervaert, "Anti-endothelial cell antibodies in systemic sclerosis," *Annals of the Rheumatic Diseases*, vol. 69, no. 2, pp. 319–324, 2010.
- [23] R. Karasawa, K. Yudoh, S. Ozaki, and T. Kato, "Anti-endothelial cell antibodies (AECA) in patients with systemic vasculitis: our research using proteomics," *Expert Opinion on Biological Therapy*, vol. 11, no. 1, pp. 77–87, 2011.
- [24] Y. Renaudineau, C. Dugué, M. Dueymes, and P. Youinou, "Antiendothelial cell antibodies in systemic lupus erythematosus," *Autoimmunity Reviews*, vol. 1, no. 6, pp. 365–372, 2002.
- [25] N. Ronda, S. Leonardi, G. Orlandini et al., "Natural anti-endothelial cell antibodies (AECA)," *Journal of Autoimmunity*, vol. 13, no. 1, pp. 121–127, 1999.
- [26] A. Servettaz, P. Guilpain, N. Tamas, S. V. Kaveri, L. Camoin, and L. Mouthon, "Natural anti-endothelial cell antibodies," *Autoimmunity Reviews*, vol. 7, no. 6, pp. 426–430, 2008.
- [27] C. Page, M. Rose, M. Yacoub, and R. Pigott, "Antigenic heterogeneity of vascular endothelium," *American Journal of Pathology*, vol. 141, no. 3, pp. 673–683, 1992.
- [28] K. Miura, K. Aoun, S. Yoshida, and Y. Kurosawa, "Autoantibodies directed against labile epitopes on cell surface proteins in autoimmune disease patients: proposal of a novel ELISA for the detection of anti-endothelial cell antibodies," *Journal of Immunological Methods*, vol. 382, no. 1–2, pp. 32–39, 2012.
- [29] M. Damjanovich, B. Gilburd, J. George et al., "Pathogenic role of anti-endothelial cell antibodies in vasculitis: an idiotypic experimental model," *Journal of Immunology*, vol. 156, no. 12, pp. 4946–4951, 1996.
- [30] S. K. Chauhan, N. K. Tripathy, and S. Nityanand, "Antigenic targets and pathogenicity of anti-aortic endothelial cell antibodies in Takayasu arteritis," *Arthritis and Rheumatism*, vol. 54, no. 7, pp. 2326–2333, 2006.
- [31] N. Del Papa, L. Guidali, M. Sironi et al., "Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion," *Arthritis and Rheumatism*, vol. 39, no. 5, pp. 758–766, 1996.
- [32] S. S. Ahmed, F. K. Tan, F. C. Arnett, L. Jin, and Y. J. Geng, "Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies," *Arthritis and Rheumatism*, vol. 54, no. 7, pp. 2250–2262, 2006.
- [33] N. K. Tripathy, S. Upadhyaya, N. Sinha, and S. Nityanand, "Complement and cell mediated cytotoxicity by antiendothelial cell antibodies in Takayasu's arteritis," *Journal of Rheumatology*, vol. 28, no. 4, pp. 805–808, 2001.
- [34] D. Y. M. Leung, J. L. Moake, P. L. Havens, M. Kim, and J. S. Pober, "Lytic anti-endothelial cell antibodies in haemolytic-uraemic syndrome," *Lancet*, vol. 2, no. 8604, pp. 183–186, 1988.
- [35] M. Fujieda, N. Oishi, and T. Kurashige, "Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment," *Clinical & Experimental Immunology*, vol. 107, no. 1, pp. 120–126, 1997.
- [36] S. H. Tannenbaum, R. Finko, and D. B. Cines, "Antibody and immune complexes induce tissue factor production by human endothelial cells," *Journal of Immunology*, vol. 137, no. 5, pp. 1532–1537, 1986.
- [37] Y. Renaudineau, E. Grunebaum, I. Krause et al., "Anti-endothelial cell antibodies (AECA) in systemic sclerosis—increased sensitivity using different endothelial cell substrates and association with other autoantibodies," *Autoimmunity*, vol. 33, no. 3, pp. 171–179, 2001.
- [38] A. Bordron, M. Dueymes, Y. Levy et al., "Anti-endothelial cell antibody binding makes negatively charged phospholipids accessible to antiphospholipid antibodies," *Arthritis & Rheumatism*, vol. 41, no. 10, pp. 1738–1747, 1998.
- [39] R. Sgonc, M. S. Gruschwitz, G. Boeck, N. Sepp, J. Gruber, and G. Wick, "Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95," *Arthritis & Rheumatism*, vol. 43, no. 11, pp. 2550–2562, 2000.
- [40] J. Matsuda, M. Gotoh, K. Gohchi, K. Kawasugi, M. Tsukamoto, and N. Saitoh, "Anti-endothelial cell antibodies to the endothelial hybridoma cell line (EAhy926) in systemic lupus erythematosus patients with antiphospholipid antibodies," *British Journal of Haematology*, vol. 97, no. 1, pp. 227–232, 1997.
- [41] M. Dieudé, J. L. Sénécal, and Y. Raymond, "Induction of endothelial cell apoptosis by heat-shock protein 60-reactive

- antibodies from anti-endothelial cell autoantibody-positive systemic lupus erythematosus patients," *Arthritis and Rheumatism*, vol. 50, no. 10, pp. 3221–3231, 2004.
- [42] P. Margutti, P. Matarrese, F. Conti et al., "Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis," *Blood*, vol. 111, no. 9, pp. 4559–4570, 2008.
- [43] J. E. Alard, S. Hillion, L. Guillevin et al., "Autoantibodies to endothelial cell surface ATP synthase, the endogenous receptor for hsp60, might play a pathogenic role in vasculitides," *PLoS One*, vol. 6, no. 2, article e14654, 2011.
- [44] Y. Renaudineau, R. Revelen, Y. Levy et al., "Anti-endothelial cell antibodies in systemic sclerosis," *Clinical and Diagnostic Laboratory Immunology*, vol. 6, no. 2, pp. 156–160, 1999.
- [45] D. W. Koenig, L. Barley-Maloney, and T. O. Daniel, "A western blot assay detects autoantibodies to cryptic endothelial antigens in thrombotic microangiopathies," *Journal of Clinical Immunology*, vol. 13, no. 3, pp. 204–211, 1993.
- [46] N. Del Papa, D. Gambini, and P. L. Meroni, "Anti-endothelial cell antibodies and autoimmune diseases," *Clinical Reviews in Allergy*, vol. 12, no. 3, pp. 275–286, 1994.
- [47] S. Praprotnik, M. Blank, P. L. Meroni, B. Rozman, A. Eldor, and Y. Shoenfeld, "Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications," *Arthritis & Rheumatism*, vol. 44, no. 7, pp. 1484–1494, 2001.
- [48] C. Jamin, C. Dugué, J. Alard et al., "Induction of endothelial cell apoptosis by the binding of anti-endothelial cell antibodies to Hsp60 in vasculitis-associated systemic autoimmune diseases," *Arthritis and Rheumatism*, vol. 52, no. 12, pp. 4028–4038, 2005.
- [49] R. Karasawa, M. S. Kurokawa, K. Yudoh, K. Masuko, S. Ozaki, and T. Kato, "Peroxiredoxin 2 is a novel autoantigen for anti-endothelial cell antibodies in systemic vasculitis," *Clinical & Experimental Immunology*, vol. 161, no. 3, pp. 459–470, 2010.
- [50] T. Kikuchi, Y. Yoshida, T. Morioka, F. Gejyo, and T. Oite, "Human voltage-dependent anion selective channel 1 is a target antigen for antiglomerular endothelial cell antibody in mixed connective tissue disease," *Modern Rheumatology*, vol. 18, no. 6, pp. 570–577, 2008.
- [51] Y. Renaudineau, C. Dugué, M. Dueymes, and P. Youinou, "Anti-endothelial cell antibodies in systemic lupus erythematosus," *Autoimmunity Reviews*, vol. 1, no. 6, pp. 365–372, 2002.
- [52] K. H. Lee, H. S. Chung, H. S. Kim et al., "Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behcet's disease," *Arthritis and Rheumatism*, vol. 48, no. 7, pp. 2025–2035, 2003.
- [53] P. García de la Peña-Lefebvre, Y. Chanseaud, M. C. Tamby et al., "IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients," *Clinical Immunology*, vol. 111, no. 3, pp. 241–251, 2004.
- [54] A. Servettaz, M. C. Tamby, P. Guilpain et al., "Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B)," *Clinical Immunology*, vol. 120, no. 2, pp. 212–219, 2006.
- [55] M. Dieudé, J. L. Senécal, and Y. Raymond, "Induction of endothelial cell apoptosis by heat-shock protein 60-reactive antibodies from anti-endothelial cell autoantibody-positive systemic lupus erythematosus patients," *Arthritis and Rheumatism*, vol. 50, no. 10, pp. 3221–3231, 2004.
- [56] M. Kaneko, T. Ono, T. Matsubara et al., "Serological identification of endothelial antigens predominantly recognized in Kawasaki disease patients by recombinant expression cloning," *Microbiology and Immunology*, vol. 48, no. 9, pp. 703–711, 2004.
- [57] H. Direskeneli, D. D'Cruz, M. A. Khamashta, and G. R. V. Hughes, "Autoantibodies against endothelial cells, extracellular matrix, and human collagen type IV in patients with systemic vasculitis," *Clinical Immunology and Immunopathology*, vol. 70, no. 3, pp. 206–210, 1994.
- [58] P. Heeringa and J. W. Tervaert, "Pathophysiology of ANCA-associated vasculitides: are ANCA really pathogenic?" *Kidney International*, vol. 65, no. 5, pp. 1564–1567, 2004.
- [59] T. Kitamura, Y. Koshino, F. Shibata et al., "Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics," *Experimental Hematology*, vol. 31, no. 11, pp. 1007–1014, 2003.
- [60] S. Morita, T. Kojima, and T. Kitamura, "Plat-E: an efficient and stable system for transient packaging of retroviruses," *Gene Therapy*, vol. 7, no. 12, pp. 1063–1066, 2000.
- [61] S. E. Lacy, C. G. Bönnemann, E. A. Buzney, and L. M. Kunkel, "Identification of FLRT1, FLRT2, and FLRT3: a novel family of transmembrane leucine-rich repeat proteins," *Genomics*, vol. 62, no. 3, pp. 417–426, 1999.
- [62] C. Lawson and S. Wolf, "ICAM-1 signaling in endothelial cells," *Pharmacological Reports*, vol. 61, no. 1, pp. 22–32, 2009.
- [63] O. Durieu-Trautmann, N. Chaverot, S. Cazaubon, A. D. Strosberg, and P. O. Couraud, "Intercellular adhesion molecule 1 activation induces tyrosine phosphorylation of the cytoskeleton-associated protein cortactin in brain microvessel endothelial cells," *Journal of Biological Chemistry*, vol. 269, no. 17, pp. 12536–12540, 1994.
- [64] R. Rothlein, T. K. Kishimoto, and E. Mainolfi, "Cross-linking of ICAM-1 induces co-signaling of an oxidative burst from mononuclear leukocytes," *Journal of Immunology*, vol. 152, no. 5, pp. 2488–2495, 1994.
- [65] S. Etienne-Manneville, J. B. Manneville, P. Adamson, B. Wilbourn, J. Greenwood, and P. O. Couraud, "ICAM-1-coupled cytoskeletal rearrangements and transendothelial lymphocyte migration involve intracellular calcium signaling in brain endothelial cell lines," *Journal of Immunology*, vol. 165, no. 6, pp. 3375–3383, 2000.
- [66] C. Lawson, M. Ainsworth, M. Yacoub, and M. Rose, "Ligation of ICAM-1 on endothelial cells leads to expression of VCAM-1 via a nuclear factor-kappaB-independent mechanism," *Journal of Immunology*, vol. 162, no. 5, pp. 2990–2996, 1999.
- [67] H. Sano, N. Nakagawa, R. Chiba, K. Kurasawa, Y. Saito, and I. Iwamoto, "Cross-linking of intercellular adhesion molecule-1 induces interleukin-8 and RANTES production through the activation of MAP kinases in human vascular endothelial cells," *Biochemical and Biophysical Research Communications*, vol. 250, no. 3, pp. 694–698, 1998.
- [68] C. Lawson, M. E. Ainsworth, A. M. McCormack, M. Yacoub, and M. L. Rose, "Effects of cross-linking ICAM-1 on the surface of human vascular smooth muscle cells: induction of VCAM-1 but no proliferation," *Cardiovascular Research*, vol. 50, no. 3, pp. 547–555, 2001.
- [69] E. Schmid, T. H. Muller, R. M. Budzinski, K. Binder, and K. Pfizenmaier, "Signaling by E-selectin and ICAM-1 induces endothelial tissue factor production via autocrine secretion of platelet-activating factor and tumor necrosis factor alpha," *Journal of Interferon and Cytokine Research*, vol. 15, no. 9, pp. 819–825, 1995.

- [70] Y. Koyama, Y. Tanaka, K. Saito et al., "Cross-linking of intercellular adhesion molecule 1 (CD54) induces AP-1 activation and IL-1beta transcription," *Journal of Immunology*, vol. 157, no. 11, pp. 5097–5103, 1996.
- [71] C. Lawson, A. L. Holder, R. E. Stanford, J. Smith, and M. L. Rose, "Anti-intercellular adhesion molecule-1 antibodies in sera of heart transplant recipients: a role in endothelial cell activation," *Transplantation*, vol. 80, no. 2, pp. 264–271, 2005.
- [72] A. F. Kavanaugh, H. Schulze-Koops, L. S. Davis, and P. E. Lipsky, "Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody," *Arthritis and Rheumatism*, vol. 40, no. 5, pp. 849–853, 1997.
- [73] B. Thuresson, J. S. Westman, and M. L. Olsson, "Identification of a novel A4GALT exon reveals the genetic basis of the P1/P2 histo-blood groups," *Blood*, vol. 117, no. 2, pp. 678–687, 2011.
- [74] R. Steffensen, K. Carlier, J. Wiels et al., "Cloning and expression of the histo-blood group P<sup>k</sup>UDP-galactose: Gal $\beta$ 1–4Glc $\beta$ 1-Cer  $\alpha$ 1,4-galactosyltransferase. Molecular genetic basis of the p phenotype," *Journal of Biological Chemistry*, vol. 275, no. 22, pp. 16723–16729, 2000.
- [75] M. Mangeney, C. A. Lingwood, S. Taga, B. Caillou, T. Tursz, and J. Wiels, "Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen," *Cancer Research*, vol. 53, no. 21, pp. 5314–5319, 1993.
- [76] L. L. W. Cooling, K. E. Walker, T. Gille, and T. A. W. Koerner, "Shiga toxin binds human platelets via globotriaosylceramide (P(K) antigen) and a novel platelet glycosphingolipid," *Infection and Immunity*, vol. 66, no. 9, pp. 4355–4366, 1998.
- [77] C. A. Lingwood, "Verotoxin-binding in human renal sections," *Nephron*, vol. 66, no. 1, pp. 21–28, 1994.
- [78] K. Lindstrom, A. E. G. K. Von dem Borne, M. E. Breimer et al., "Glycosphingolipid expression in spontaneously aborted fetuses and placenta from blood group p women. Evidence for placenta being the primary target for anti-Tja-antibodies," *Glycoconjugate Journal*, vol. 9, no. 6, pp. 325–329, 1992.





# Ghrelin attenuates collagen production in lesional fibroblasts from patients with systemic sclerosis☆

Yuko Ota, Yasushi Kawaguchi\*, Kae Takagi, Hisae Ichida, Takahisa Gono, Masanori Hanaoka, Tomoaki Higuchi, Hisashi Yamanaka

*Institute of Rheumatology, Tokyo Women's Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054 Japan*

Received 10 January 2013; accepted with revision 5 March 2013

Available online 13 March 2013

## KEYWORDS

Ghrelin;  
Systemic sclerosis;  
Fibrosis;  
Interstitial lung disease

**Abstract** Systemic sclerosis (SSc) is a connective tissue disease characterized by thickening of the skin and tissue fibrosis of the internal organs. Ghrelin is primarily described as a gut hormone, and many studies currently indicate that ghrelin has protective effects in different organs, including the heart, pancreas, lung and liver, resulting from its anti-fibrotic properties. We found decreased levels of ghrelin in the plasma from patients with SSc compared with those from healthy controls. In skin fibroblast cultures, recombinant ghrelin diminished the production of collagen type I. In addition, the mRNA levels of *COL1A2* and *TGFB* genes were significantly decreased by the stimulation of ghrelin. We showed that ghrelin may exert anti-fibrotic effects in the skin fibroblasts from patients with SSc. Because the plasma levels of ghrelin are low in SSc, the administration of ghrelin could be a new strategy for the treatment of SSc.

© 2013 Elsevier Inc. All rights reserved.

## 1. Introduction

Systemic sclerosis (SSc) is a multisystem disorder of connective tissue characterized by the excessive accumulation of extracellular matrix in the skin and various internal organs [1,2]. Although the pathogenesis of SSc is not fully understood, autoimmunity may be involved because the production of SSc-specific autoantibodies has been well established for the past two decades, including anti-topoisomerase I antibody, anti-centromere antibody, and anti-RNA polymerase I/III antibody [3]. Fibrosis and endothelial injury are the

central manifestations of SSc [4]. Skin fibrosis, interstitial lung disease, gastrointestinal involvement, and cardiac involvement may result from the fibrosis [5]. The pathological examinations of the tissue fibrosis revealed the abnormality of extracellular matrix production in the lesional tissues of patients with SSc [6]. More than 90% of patients with SSc develop gastrointestinal tract involvement [7], but severe manifestations such as pseudo-obstruction, severe constipation, megacolon and malabsorption syndrome are rarely observed in patients with SSc. Although intestinal involvement is believed to result from smooth muscle fibrosis [8], the pathophysiology of the intestinal involvement is not fully understood. Unfortunately, intestinal involvement is often detected when severe complications have already occurred, and it is irreversible and difficult to manage [9]. Therefore, finding new treatments for the organ fibrosis associated with SSc is extremely important.

☆ This work is supported by systemic sclerosis and mixed connective tissue disease research grants from the Ministry of Health, Labour and Welfare, Japan.

\* Corresponding author. Fax: +81 3 5269 1726.

E-mail address: [y-kawa@ior.twmu.ac.jp](mailto:y-kawa@ior.twmu.ac.jp) (Y. Kawaguchi).

Ghrelin, a 28-amino-acid peptide with n-octanoylation indispensable for binding to the growth hormone secretagogue receptor (GHSR), was originally discovered in human and rat stomachs in 1999 [10]. Ghrelin molecules are present as two major endogenous forms, an acylated ghrelin and a desacylated ghrelin [11]. The modification is highly susceptible to circulating esterases, which can convert the active form of ghrelin (acylated form) to the desacylated form [12]. This conversion can occur within minutes after sample collection and can lead to variability and distracting artifacts in acylated ghrelin measurements. In addition to potent growth hormone-releasing effects, ghrelin has been found to have other peripheral effects. Although ghrelin mRNA is particularly abundant in the stomach and intestine, it is also expressed at low levels in other organs, notably, the brain, pituitary gland, heart, lung, pancreas, kidney, and placenta [13]. One of the most important biological activities of ghrelin is the stimulation of food intake during the long-term regulation of body weight [14]. The wide distribution of the GHSR in various organs suggests a potentially broad array of actions for ghrelin. Recently, in addition to growth hormone-releasing effects, peripheral effects such as cytoprotection, vasodilatation, and anti-inflammation have been attributed to ghrelin [15,16].

Plasma ghrelin levels increase upon fasting and insulin-induced hypoglycemia and decrease in response to the oral or intravenous administration of glucose. The fasting plasma ghrelin level is elevated in anorexia nervosa and cachexia and is reduced in obesity [17,18]. In autoimmune diseases, the serum ghrelin levels have been measured in patients with rheumatoid arthritis and ANCA-associated vasculitis [19,20]. In patients with rheumatoid arthritis, the serum ghrelin levels did not differ from those of the healthy group. Conversely, the serum ghrelin levels were significantly elevated in patients with ANCA-associated vasculitis compared with the healthy controls (HCs), and the levels were correlated with disease activity.

In 2008, rikkunshito, an herbal medicine, was shown to suppress cisplatin-induced anorexia in rats by increasing the plasma acylated ghrelin. Recent studies also indicated that recombinant ghrelin was successfully administered to patients with a variety of disorders, such as anorexia, caquexia, and gastroparesis [21]. Moreover, ghrelin improves the functional capacity in elderly patients with congestive heart failure and chronic obstructive pulmonary disease, which might be due to its anti-fibrotic effects.

The aim of this study was to investigate the levels of acylated and desacylated ghrelin in the plasma of patients with SSc. We also estimated the association between the plasma ghrelin levels and disease phenotypes, such as organ involvement, limited or diffuse cutaneous types and SSc-specific autoantibodies. In addition, we evaluated the biological functions of ghrelin in skin fibroblasts derived from patients with SSc.

## 2. Patients and methods

### 2.1. Patients

Blood samples were obtained from 45 Japanese patients with SSc (38 female and 7 male). All patients fulfilled the criteria for SSc proposed by the American College of Rheumatology [22]. Patients were grouped according to the classification

system proposed by LeRoy et al. [23]. The baseline characteristics are shown in Table 1. Twenty seven healthy Japanese individuals were enrolled in the present study as HCs (22 female and 5 male; median age: 52 years old). Informed consent was obtained from each patient and each healthy donor.

### 2.2. Assessment of clinical characteristics

Skin thickness was quantified using the modified Rodnan total skin thickness score (TSS, maximum possible score: 51) [24]. Interstitial lung disease (ILD) was assessed by chest radiography and high-resolution computed tomography (HRCT). Using HRCT, we defined the presence of the following as indicating ILD: a ground-glass appearance, a reticular pattern, and a honeycomb pattern. All patients were assessed by echocardiography, and all patients with a right ventricular systolic pressure of greater than 40 mm Hg underwent right ventricular catheterization. Pulmonary arterial hypertension (PAH) was defined as a mean pulmonary artery pressure of 25 mm Hg or greater and a pulmonary capillary wedge pressure of 15 mm Hg or less at rest [25]. Scleroderma renal crisis (SRC) was defined as malignant arterial hypertension, rapidly progressive renal failure and/or microangiopathic hemolytic anemia (MHA). Patients with hypertension of recent onset without increases in serum creatinine levels or MHA were not categorized as having SRC. A digital ulcer (DU) was defined as a fingertip or toe ulceration that occurred more than once a year. Esophagus involvement was defined as hypomotility shown by barium radiography or esophageal reflux shown by FGS. Intestinal involvement was defined as the presence of malabsorption syndrome, episodes of pseudo-obstruction and/or the need for parenteral hyperalimentation.

**Table 1** Baseline characteristics of the patients and healthy controls.

	SSc (n = 45)	HC (n = 27)
Age, years, median (range)	57 (18–73)	52 (32–70)
Gender, female:male	38:7	22:5
Clinical features		
dcSSc, no (%)	36 (80)	
ILD, no (%)	30 (67)	
PAH, no (%)	8 (18)	
SRC, no (%)	3 (7)	
Esophageal reflux, no (%)	37 (82)	
Intestinal involvement, no (%)	2 (4)	
DU, no (%)	16 (36)	
Autoantibodies		
ANA, no (%)	44 (98)	ND
Topo, no (%)	24 (53)	ND
U1RNP, no (%)	8 (18)	ND
CENP, no (%)	9 (20)	ND

SSc, systemic sclerosis; HC, healthy controls; dcSSc, diffuse cutaneous SSc; ILD, interstitial lung disease; PAH, pulmonary arterial hypertension; SRC, scleroderma renal crisis; DU, digital ulcer; ANA, anti-nuclear antibody; Topo, anti-topoisomerase I antibody; CENP, anti-centromere antibody; U1RNP, anti-U1RNP antibody.



### 2.3. Detection of autoantibodies

The presence of CENP was determined by the distinctive indirect immunofluorescence pattern of HEp-2 cells and by an enzyme immunoassay (MESACUP-2 Test, Medical & Biological Lab, Nagoya, Japan). Both Topo I and U1RNP were determined by double immunodiffusion against calf thymus extracts with commercially available kits (Medical & Biological Lab).

### 2.4. Measurement of plasma acylated ghrelin and desacylated ghrelin

Blood samples were immediately transferred to chilled polypropylene tubes containing EDTA-2Na (1 mg/ml) and aprotinin (500 U/ml) and centrifuged at 4 °C. Hydrochloric acid (1 N) was added to samples at 10% of the plasma volume immediately after the separation of the plasma, and the plasma sample was stored at -80 °C until assayed. The levels of acylated and desacylated ghrelin were measured using two commercially available enzyme-linked immunosorbent assay (ELISA) kits (Mitsubishi Chemical Medience, Tokyo, Japan). The minimal detection limits of acylated ghrelin and desacylated ghrelin in this assay were 2.5 and 12.5 fmol/ml, respectively.

### 2.5. Cell culture

Skin biopsies from the dorsal forearm were performed as a diagnostic procedure in 5 patients with SSc. No medical interventions, such as corticosteroids or immunosuppressive agents, were performed before the skin biopsy. The fibroblasts were cultured in Dulbecco's Modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (Invitrogen). Dermal fibroblasts from passages 3–5 were used for the experiments.

### 2.6. Measurement of type I collagen

Cultured fibroblasts were prepared at a density of  $2 \times 10^4$  cells/well in 24-well culture plates with DMEM plus 10% FBS. After 24 h of culture, the medium was removed, and the cells were cultured in serum-free medium (QBSF-51, Sigma-Aldrich, St. Louis, MO). To assess the effect of ghrelin, skin fibroblasts were cultured with recombinant human ghrelin (Peptide Inc., Minoh, Japan) dissolved in phosphate-buffered saline at concentrations of 10–1000 nM for 24–72 h. The supernatants were collected and stored at -80 °C. Procollagen type I C-peptide was measured using an ELISA kit (Takara Shuzo, Kyoto, Japan).

### 2.7. Quantitative reverse transcription-polymerase chain reaction (RT-PCR)

RNAs were extracted using TRIzol Reagent (Invitrogen) according to the manufacturer's instructions. For the real-time PCR analysis, total RNA was treated with DNase I (Invitrogen), and cDNA was generated using SuperScript III (Invitrogen) with oligo dT primers. The real-time PCR analysis was conducted on Chromo4 (Bio-Rad, Hercules, CA) using the TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA) for *GHSR1A*, *COL1A2*, *TGFB* and *GAPDH*.

### 2.8. GHSR1 expression in SSc fibroblasts

GHSR1 expression was analyzed by immunohistochemical staining. Briefly, SSc skin fibroblasts were plated on an 8-chamber slide, cultured for 72 h and used for immunostaining. The samples were washed three times with PBS and fixed in 2% paraformaldehyde (PFA) (Alfa Aesar, Ward Hill, MA) and 0.1% Triton X-100 (Sigma-Aldrich) in PBS for 1 h. After washing three times with PBS, the cells were incubated with a blocking solution (Dako Japan, Tokyo, Japan) for 20 min at room temperature. Excess blocking solution was drained, and the samples were incubated with anti-GHSR1a antibodies (Phoenix Pharmaceuticals Inc., Burlingame, CA) for 30 min at room temperature. The samples were then rinsed with PBS and incubated with a biotinylated secondary antibody (Vector Lab, Burlingame, CA) for 30 min. The staining was developed using the diaminobenzidine substrate (Dako Japan), and counterstaining was performed with hematoxylin. The samples were photographed with a photomicroscope (Olympus, Tokyo, Japan).

### 2.9. Statistical analysis

A *student's t*-test was used to compare plasma acylated ghrelin and desacylated ghrelin levels, and Fisher's exact probability test was used to compare the frequencies of 2 groups. The Mann–Whitney U test was used to compare the total skin thickness score (TSS) between the 2 groups of patients with SSc. A probability (*P*) value of <0.05 was considered significant.

## 3. Results


### 3.1. Plasma ghrelin levels in SSc

The levels of acylated ghrelin and desacylated ghrelin in the plasma samples from patients with SSc and the HCs were assessed by ELISA (Figs. 1A and B). The levels of plasma acylated ghrelin were  $13.6 \pm 6.3$  fmol/ml in the patients with SSc and  $22.7 \pm 8.8$  fmol/ml in the HCs. The levels of plasma desacylated ghrelin were  $72.8 \pm 38.6$  fmol/ml in the patients with SSc and  $152.9 \pm 84.5$  fmol/ml in the HCs. Both acylated ghrelin and desacylated ghrelin concentrations were significantly lower in the patients with SSc than in the HCs ( $P < 0.0001$ ). The ratio of acylated ghrelin and desacylated ghrelin was not different between the patients with SSc and the HCs (Fig. 1C).

In the SSc subgroups, the levels of acylated ghrelin in the patients with dcSSc ( $P < 0.0001$ ) and lcSSc ( $P = 0.035$ ) were significantly lower than those in the HCs (Fig. 2A). There were no significant differences in the plasma acylated ghrelin levels between the patients with dcSSc and those with lcSSc ( $P = 0.27$ , Fig. 2A).

### 3.2. Association between the clinical features of patients with SSc and plasma ghrelin levels


Fibrosis and endothelial injury are the central manifestations of SSc. To investigate which of these manifestations is associated with ghrelin levels, we estimated the association



**Figure 1** Levels of acylated ghrelin (A) and desacylated ghrelin (B) and the ratio of acylated to desacylated ghrelin (C) in patients with systemic sclerosis (SSc). The levels of both acylated and desacylated ghrelins were significantly decreased in patients with SSc ( $P < 0.0001$ ) compared with healthy controls (HC). The ratio of acylated to desacylated ghrelin in patients with SSc was similar to that in HC.

between the acylated ghrelin level and the clinical manifestations, such as skin fibrosis, ILD, PAH, SRC, esophageal reflux, intestinal involvement, DU, and autoantibodies. Values lower than the mean  $-1$  SD (13.9 fmol/l) of the levels of acylated

ghrelin in healthy individuals were considered to be an abnormally low range. We assessed the clinical features between the low and normal levels of acylated ghrelin in patients with SSc. As shown in Table 2, decreased acylated ghrelin levels



**Figure 2** Levels of acylated ghrelin in patients with systemic sclerosis (SSc). (A) The concentrations of acylated ghrelin were measured in both diffuse cutaneous type (dcSSc) and limited cutaneous type (lcSSc). There was no significant difference in the levels of acylated ghrelin between dcSSc and lcSSc. (B) The concentrations of acylated ghrelin were measured in SSc patients with and without interstitial lung disease (ILD). The levels of acylated ghrelin in patients with SSc and ILD were significantly higher than those in patients with SSc in the absence of ILD ( $P = 0.025$ ).

**Table 2** Clinical and laboratory findings among SSc patients with elevated acylated ghrelin levels.

	Acylated ghrelin ≤ 13.9 fmol/ml	Acylated ghrelin > 13.9 fmol/ml	<i>P</i>	OR	95% CI
Number of patients	24	21			
Sex, M:F	5:19	2:19			
Disease pattern, D:L	20:4	16:5	0.55	1.6	0.4–6.8
Clinical features					
TSS, mean ± SD	22 ± 9	16 ± 9	0.081		
Organ involvement					
ILD, no (%)	21 (88)	9 (43)	0.0015	9.3	2.1–41.3
PAH, no (%)	6 (25)	2 (10)	0.18	3.2	0.6–17.8
SRC, no (%)	2 (8)	1 (5)	0.63	1.8	0.2–21.6
Esophagus, no (%)	20 (83)	17 (81)	0.83	1.2	0.3–5.4
Intestinal involvement, no (%)	2 (8)	0 (0)	0.18	–	–
DU, no (%)	7 (29)	9 (43)	0.45	0.6	0.2–2.2
Autoantibodies					
ANA, no (%)	24 (100)	20 (95)	0.28	–	–
Topo, no (%)	14 (58)	10 (48)	0.47	1.5	0.5–5.0
U1RNP, no (%)	4 (17)	4 (19)	0.83	0.9	0.2–3.9
CENP, no (%)	3 (13)	6 (29)	0.18	0.4	0.1–1.7

TSS, total skin thickness score; ILD, interstitial lung disease; PAH, pulmonary arterial hypertension; SRC, scleroderma renal crisis; DU, digital ulcer; ANA, anti-nuclear antibody; Topo, anti-topoisomerase I antibody; CENP, anti-centromere antibody; U1RNP, anti-U1RNP antibody.

were observed in 53% (24/45) of all SSc patients, 56% (20/36) of dcSSc patients, and 56% (4/9) of lcSSc patients. The frequency of ILD in patients with decreased acylated ghrelin levels was significantly higher than that in patients with normal acylated ghrelin levels (88% versus 43%;  $P = 0.0015$ , OR: 9.3; 95% CI: 2.1–41.3).

Consistent with these observations, the plasma levels of acylated ghrelin were significantly lower in SSc patients with ILD than those without ILD ( $P = 0.025$ , Fig. 2B). Additionally, the TSS values in patients with decreased acylated ghrelin levels showed a tendency to be higher than those in patients with normal acylated ghrelin levels ( $P = 0.081$ , Table 2).

### 3.3. GHSR1A expression in skin fibroblasts of patients with SSc

To estimate the expression of GHSR1a (the growth hormone secretagogue receptor 1a), which is a ligand of acylated ghrelin in skin fibroblasts, we examined the mRNA and protein levels. As shown in Fig. 3A, the *GHSR1A* was expressed at the transcriptional level in skin fibroblasts from both SSc patients and normal individuals, and there was no difference in the expression levels between the two groups. Immunohistochemical staining using a specific anti-GHSR1a antibody revealed that the expression of GHSR1a was detected in cultured skin fibroblasts from both SSc patients and normal controls (Fig. 3B).

### 3.4. Effects of ghrelin on collagen production in skin fibroblasts derived from patients with SSc


Thus, we explored the effects of ghrelin on collagen production in skin fibroblasts derived from patients with SSc. Skin fibroblasts derived from 5 patients with SSc were used in the present study. In the experiments in vitro, procollagen

type I C-peptide production was significantly suppressed by 100 nM and 1  $\mu$ M ghrelin in cultured SSc fibroblasts for 72 h ( $P < 0.05$ , Fig. 4). To determine whether the inhibitory effect of ghrelin on collagen type I occurred at the transcription or post-transcription level, real-time RT-PCR was performed. The levels of *COL1A2* mRNA were significantly decreased by ghrelin stimulation (Fig. 5A). Because intrinsic TGF- $\beta$  signal transduction contributes to the development of tissue fibrosis in SSc, the effects of ghrelin on *TGFB1* expression were investigated. The analysis of real-time RT-PCR using specific primers for *TGFB1* revealed the inhibitory effects of ghrelin on the mRNA levels of *TGFB1* (Fig. 5B).

## 4. Discussion

Ghrelin is a gut hormone that is also produced by extra-intestinal tissues and exerts a variety of pleiotropic effects in parenchymal cells [26]. We measured the plasma ghrelin levels (both acylated and desacylated) in patients with SSc. The present study was the first to show that both acylated and desacylated ghrelin levels were significantly decreased in the plasma from patients with SSc compared with those from healthy donors. The ratio of acylated to desacylated ghrelin was not different between patients with SSc and healthy donors. These findings suggest that the production of total ghrelin in SSc patients is diminished but that enzymatic acylation after translation may be normally regulated in SSc patients as well as healthy individuals. We also showed that the patients with low levels of acylated ghrelin had a significantly higher rate of ILD and that the levels of TSS tended to be associated with low acylated ghrelin levels. These results indicated that the levels of acylated ghrelin were inversely correlated with tissue fibrosis.


Ghrelin is predominantly produced by a distinct type of endocrine cell in the gastric oxyntic glands [27]. Involvement




**Figure 3** Expression of growth hormone secretagogue receptor (GHSR)1 mRNA and protein in skin fibroblasts. (A) RT-PCR demonstrated the presence of *GHSR1A* mRNA in skin fibroblasts from both systemic sclerosis (SSc) patients and normal individuals, and there was no difference in the expression levels between the two groups. (B) The expression of GHSR1a in skin fibroblasts derived from patients with SSc was estimated by immunohistochemistry. The left panel shows the staining using the negative control IgG, and the right panel shows positive staining using the anti-GHSR1a antibody.

of the upper intestinal tracts, including the esophagus and stomach, is a common complication in patients with SSc [8]. The clinical features of the stomach are gastroparesis and

telangiectasia, resulting in atrophy of the acid-secreting mucosa with a resultant loss of feedback to antral gastrin release [28]. These patients frequently had atrophy of the



**Figure 4** Effect of ghrelin on collagen production in cultured skin fibroblasts from patients with systemic sclerosis (SSc). The fibroblasts were exposed to 0–1000 nM ghrelin for 24–72 h. In 72 h, recombinant ghrelin diminished the production of collagen type I in a dose-dependent manner.



**Figure 5** Expression of COL1A2 (A) and TGFBI (B) mRNAs in skin fibroblasts exposed to 100 nM ghrelin for 24 h. Recombinant ghrelin exerted the inhibitory effects in the transcription of COL1A2 and TGFBI.

oxyntic gland mucosa. This clinical background in patients with SSc could explain the strikingly low levels of ghrelin in the blood.

In *in vitro* experiments, we demonstrated for the first time that recombinant ghrelin inhibited collagen type I production in skin fibroblasts. We provided evidence that ghrelin directly reduces collagen synthesis at the mRNA level in cultured skin fibroblasts. However, our observations indicated that ghrelin also exerted inhibitory effects on TGF- $\beta$ 1 expression, which may play a central role in the tissue fibrosis in SSc [29–31]. Taken together, ghrelin may be a potent regulator to suppress fibrosis directly and through the inhibition of TGF- $\beta$ 1.

In 2010, Moreno and colleagues reported that ghrelin reduced the expression of collagen type I and TGF- $\beta$ 1 in hepatic stellate cells, suggesting that ghrelin may be a candidate to treat hepatic fibrosis [32]. More recently, ghrelin was reported to ameliorate bleomycin-induced acute lung injury, which is a mouse model of lung fibrosis [33]. That report indicated that ghrelin suppressed various cytokines and growth factors and prolonged the survival of the bleomycin-treated mice. The authors suggested a novel attractive therapeutic strategy for the treatment of acute lung injury.

In conclusion, the levels of plasma ghrelin might be well inversely correlated to the severity of the fibrosis. Ghrelin exhibited an anti-fibrotic effect in skin fibroblasts *in vitro*. The administration of ghrelin could be a novel strategy for the treatment of skin and lung fibrosis in patients with SSc.

## Conflict of interest statement

The author(s) declare that there are no conflicts of interest.

## References

- [1] T.A. Medsger Jr., Systemic sclerosis (scleroderma): clinical aspects, in: W.J. Koopman (Ed.), *Arthritis and Allied Conditions*, 14th ed., Lippincott Williams & Wilkins, Philadelphia, PA, 2001, pp. 1590–1624.
- [2] J. Varga, D. Abraham, Systemic sclerosis: a prototype multi-system fibrotic disorder, *J. Clin. Invest.* 117 (2007) 557–567.
- [3] Y. Hamaguchi, Autoantibody profile in systemic sclerosis: predictive value for clinical evaluation and prognosis, *J. Dermatol.* 37 (2010) 42–53.
- [4] A. Gabrielli, E.V. Avvediment, T. Krieg, Sclerodema, *N. Engl. J. Med.* 360 (2009) 1989–2003.
- [5] T.R. Katsumoto, M.L. Whitfield, M.K. Connolly, The pathogenesis of systemic sclerosis, *Annu. Rev. Pathol.* 6 (2011) 509–537.
- [6] A. Usategui, M.J. del Rey, J.L. Pablos, Fibroblast abnormalities in the pathogenesis of systemic sclerosis, *Expert. Rev. Clin. Immunol.* 7 (2011) 491–498.
- [7] R. Domsic, K. Fasanella, K. Bielefeldt, Gastrointestinal manifestations of systemic sclerosis, *Dig. Dis. Sci.* 53 (2008) 1163–1174.
- [8] A. Forbes, I. Marie, Gastrointestinal complications: the most frequent internal complications of systemic sclerosis, *Rheumatology* 48 (Suppl. 3) (2009) iii36–iii39.
- [9] C.P. Denton, C.M. Black, D.J. Abraham, Mechanisms and consequences of fibrosis in systemic sclerosis, *Nat. Clin. Pract. Rheumatol.* 2 (2006) 134–144.
- [10] M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matuo, K. Kangawa, Ghrelin is a growth-hormone-releasing acylated peptide from stomach, *Nature* 402 (1999) 656–660.
- [11] H. Hosoda, M. Kojima, H. Matsuo, K. Kangawa, Ghrelin and des-acylated ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue, *Biochem. Biophys. Res. Commun.* 279 (2000) 1077–1080.
- [12] C. De Vriese, F. Gregoire, R. Lema-Kisoka, M. Waelbroeck, P. Robberecht, C. Delporte, Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites, *Endocrinology* 145 (2004) 4997–5005.
- [13] S. Gnanapavan, B. Kola, S.A. Bustin, D.G. Morris, P. McGee, P. Fairclough, et al., The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans, *J. Clin. Endocrinol. Metab.* 87 (2002) 2988–2991.
- [14] A.M. Wren, S.R. Bloom, Gut hormones and appetite control, *Gastroenterology* 132 (2007) 2116–2130.
- [15] W.G. Li, D. Gavrilu, X. Liu, L. Wang, S. Gunnlaugsson, L.L. Stoll, et al., Ghrelin inhibits proinflammatory responses and nuclear factor kappaB activation in human endothelial cells, *Circulation* 109 (2004) 2221–2226.
- [16] V.D. Dixit, E.M. Schaffer, R.S. Pyle, G.D. Collins, S.K. Sakthivel, R. Palaniappan, et al., Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by

- human monocytes and T cells, *J. Clin. Invest.* 114 (2004) 57–66.
- [17] T. Shinya, M. Nakazato, M. Mizuta, Y. Date, M.S. Mondal, M. Tanaka, et al., Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion, *J. Clin. Endocrinol. Metab.* 87 (2002) 240–244.
- [18] N. Nagaya, M. Uematsu, M. Kojima, Y. Date, M. Nakazato, H. Okamura, et al., Elevated circulating levels of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors, *Circulation* 104 (2001) 2034–2038.
- [19] Suleyman Serdar Koca, Metin Ozgen, Suleyman Aydin, Sait Dag, Bahri Evren, Ahmet Isik, Ghrelin and obestatin levels in rheumatoid arthritis, *Inflammation* 31 (2008) 329–335.
- [20] P. Kumper, R. Horn, G. Brabant, A. Woywodt, M. Schiffer, H. Haller, M. Haubitz, Serum leptin and ghrelin correlate with disease activity in ANCA-associated vasculitis, *Rheumatology* 47 (2008) 484–487.
- [21] H. Takeda, C. Sadakane, T. Hattori, T. Katsurada, T. Ohkawara, K. Nagai, et al., Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT<sub>2</sub> receptor antagonism, *Gastroenterology* 134 (2008) 2004–2013.
- [22] Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma), *Arthritis Rheum.* 23 (1980) 581–590.
- [23] E.C. LeRoy, C. Black, R. Fleischmajer, S. Jablonska, T. Krieg, T.A. Medsger Jr., et al., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis, *J. Rheumatol.* 15 (1988) 202–205.
- [24] P. Clements, P. Lachenbruch, J. Siebold, B. White, S. Weiner, R. Martin, et al., Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis, *J. Rheumatol.* 22 (1995) 1281–1285.
- [25] N. Galie, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, J.A. Barbera, et al., Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT), *Eur. Heart J.* 30 (2009) 2493–2537.
- [26] A.J. Van der Lely, M. Tschop, M.I. Heiman, E. Ghigo, Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin, *Endocr. Rev.* 25 (2004) 426–457.
- [27] Y. Date, M. Kojima, H. Hosoda, A. Sawagashira, M.S. Mondal, T. Suganuma, et al., Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans, *Endocrinology* 141 (2000) 4255–4261.
- [28] E.C. Ebert, Gastric and enteric involvement in progressive systemic sclerosis, *J. Clin. Gastroenterol.* 42 (2008) 5–12.
- [29] A. Jelaska, J.H. Korn, Role of apoptosis and transforming growth factor beta1 in fibroblasts selection and activation in systemic sclerosis, *Arthritis Rheum.* 43 (2000) 2230–2239.
- [30] M. Jinnin, Mechanisms of skin fibrosis in systemic sclerosis, *J. Dermatol.* 37 (2010) 11–25.
- [31] J. Varga, B. Pasche, Transforming growth factor beta as a therapeutic target in systemic sclerosis, *Nat. Rev. Rheumatol.* 5 (2009) 200–206.
- [32] M. Moreno, J.F. Chaves, P. Sancho-Bru, F. Ramalho, L.N. Ramalho, M.L. Mansago, et al., Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans, *Hepatology* 51 (2010) 974–985.
- [33] Y. Imazu, S. Yanagi, K. Miyoshi, H. Tsubouchi, S. Yamashita, N. Matsumoto, et al., Ghrelin ameliorates bleomycin-induced acute lung injury by protecting alveolar epithelial cells and suppressing lung inflammation, *Eur. J. Pharmacol.* 672 (2011) 153–158.



## Serum antibodies against the 70k polypeptides of the U1 ribonucleoprotein complex are associated with psychiatric syndromes in systemic lupus erythematosus: a retrospective study

Yasuhiro Katsumata · Yasushi Kawaguchi · Sayumi Baba · Seisuke Hattori · Koji Tahara · Kaori Ito · Tadao Iwasaki · Nozomi Yamaguchi · Hiroaki Hattori · Kinya Nagata · Yuko Okamoto · Hisashi Yamanaka · Masako Hara

Received: 5 October 2011 / Accepted: 15 February 2012 / Published online: 28 March 2012  
© Japan College of Rheumatology 2012

### Abstract

**Objectives** We assessed the association between serum autoantibodies against the 70-kDa polypeptide of the U1-ribonucleoprotein (RNP) complex (U1-70k) and the central nervous system (CNS) syndromes in systemic lupus erythematosus (SLE) patients.

**Methods** We studied 106 hospitalized patients with active SLE, comparing those with ( $n = 32$ ) and without ( $n = 74$ ) CNS syndromes. CNS syndromes were further classified into neurologic ( $n = 21$ ) and psychiatric ( $n = 15$ ) disorders. Immunoglobulin G (IgG) anti-U1-70k antibodies were measured by enzyme-linked immunosorbent assay (ELISA) using recombinant antigens. IgG antibodies against whole U1-RNP were measured using commercial ELISA kits.

**Results** Although there was no significant difference in the levels of serum anti-U1-70k antibodies in SLE patients with or without CNS syndromes ( $p = 0.83$ ), the levels were significantly elevated in SLE patients compared with

patients without psychiatric syndromes ( $p = 0.030$ ). In contrast, no significant difference was observed in the levels of serum anti-U1-RNP antibodies in SLE patients with or without psychiatric syndromes ( $p = 0.555$ ).

**Conclusions** These results indicate that serum anti-U1-70k antibodies are associated with psychiatric syndromes in SLE but that they are not associated with CNS syndromes as a whole or with neurologic syndromes. The anti-U1-70k antibodies might be involved in the pathological mechanisms of psychiatric syndromes in SLE.

**Keywords** Autoantibody · Central nervous system · Systemic lupus erythematosus

### Introduction

Central nervous system (CNS) lupus is a serious and potentially life-threatening manifestation of systemic lupus erythematosus (SLE) and occurs in 37–95 % of cases and is associated with an increased risk of death [1]. Despite the frequency and severity of CNS lupus, the lack of a diagnostic gold standard hinders the differentiation of primary CNS lupus from secondary neuropsychiatric (NP) manifestations that are unrelated to SLE at their onset [1–3]. The American College of Rheumatology (ACR) developed a standardized nomenclature system to provide case definitions for 19 NP syndromes associated with SLE, including reporting standards and recommendations for laboratory and imaging tests [2]. Although this standardized nomenclature has helped clarify a complicated situation, its usefulness as a clinical diagnostic instrument remains to be determined. A significant number of reports, including our own, found an association between NP manifestations of SLE and the presence of autoantibodies,

Y. Katsumata (✉) · Y. Kawaguchi · S. Baba · Y. Okamoto · H. Yamanaka · M. Hara  
Institute of Rheumatology, Tokyo Women's Medical University,  
10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan  
e-mail: katsumata@ior.twmu.ac.jp

S. Hattori  
Division of Cellular Proteomics (BML), Institute of Medical  
Science, University of Tokyo, Tokyo, Japan

S. Hattori  
Division of Biochemistry, School of Pharmaceutical Science,  
Kitasato University, Tokyo, Japan

K. Tahara · K. Ito · T. Iwasaki · N. Yamaguchi · H. Hattori ·  
K. Nagata  
Advanced Medical Technology and Development, BML,  
Saitama, Japan

although contradictory data are reported in some cases [1, 4–11]. Although most of these autoantibodies may merely be an epiphenomenon [7], there is some evidence that supports their pathogenic roles. The induction of depression-like behavior was demonstrated by an intracerebroventricular injection of antiribosomal P into mice [12]. It was also reported that an integral membrane protein of the neuronal cell surface was a target for antiribosomal P autoantibody and that these antibodies could cause a rapid and sustained increase in calcium ( $\text{Ca}^{2+}$ ) influx in cultured neurons through interaction with this neuronal surface P antigen, resulting in apoptotic cell death [13]. Furthermore, we reported that anti-*N*-methyl-D-aspartate receptor subunit 2A reactive antibodies decreased cell viability by  $\text{Ca}^{2+}$  influx in SLE by inhibiting the binding capacity of zinc [14]. In this context, identification and characterization of novel specific autoantibodies could help elucidate the etiology of NP manifestations that accompany SLE and open new avenues of research for devising more effective diagnostic and therapeutic strategies.

Antibodies against the U1-ribonuclear protein (U1-RNP) complex are found in serum obtained from 25 % to 47 % of SLE patients, and high titers of these antibodies are diagnostic of mixed connective tissue disease (MCTD) [15]. Anti-U1-RNP antibodies are not disease specific but, rather, are associated with manifestations such as Raynaud's phenomenon, hand swelling, synovitis, myositis, and sclerodactyly [16]. Anti-U1-RNP immunity has been implicated in the disease pathogenesis of SLE and MCTD through several methods in serial works by Greidinger and others [17–20]. U1-RNP is a nuclear protein-RNA complex that is important in the processing of messenger RNA (mRNA) [17]. It is composed of U1-RNA and contains a partially double-stranded secondary structure as well as polypeptides that are specific to the U1-RNP complex, including U1-A, U1-C, and 70-kDa polypeptide of the U1-RNP complex (U1-70k) [17]. Other proteins, such as Sm, may be associated with U1-RNP but are not specific to the U1-RNP complex [17]. The 70-kDa (70k) polypeptide is one of the major determinants of antibody response to U1-RNP. Anti-U1-70k antibodies often develop early in the U1-RNP antibody response and contribute to the development of antibodies against other proteins in the U1-RNP complex through the so-called epitope-spreading process [21].

Okada et al. [22] reported positive tests for anti-U1-RNP antibodies in the serum of 13 of the 14 patients with aseptic meningitis [eight with SLE, six with MCTD or undifferentiated connective tissue disease, and one with Sjögren's syndrome (SS)] among 1,560 patients with connective tissue disease, suggesting that anti-U1-RNP antibodies may be linked to CNS syndromes [22]. Sato et al. [23] reported that anti-U1-RNP antibodies in cerebrospinal fluid (CSF),

as determined by an RNA immunoprecipitation assay and/or an elevation in the anti-U1-RNP index, are more specific markers for CNS lupus than are indices of CSF-derived interleukin-6 (IL-6) and immunoglobulin G (IgG) in the serum of anti-U1-RNP-antibody-positive patients with SLE or MCTD. We assessed the association of serum anti-U1-70k antibodies with CNS syndromes in SLE patients.

## Patients and methods

### Study participants and sample collection

From 1994 through 2007, serum samples from 106 patients with active SLE were obtained using the Tokyo Women's Medical University SLE Database. All patients were positive for four or more of the revised ACR (formerly the American Rheumatism Association) criteria for SLE [24, 25] and gave informed consent for participation. Because we wanted to compare recently diagnosed active CNS lupus patients to non-NP-SLE patients, those who had non-SLE-related NP manifestations arising from infection, uremia, electrolyte imbalance, hypoxia, brain tumors, trauma, primary mental diseases, drug use, or past histories of NP involvement were excluded because unrelated conditions could have affected current symptoms or laboratory findings. At the time of the serum collection, each patient completed a standardized medical history and was given a physical examination that included neurologic and rheumatologic assessments. Full psychiatric battery recommended by the ACR [2, 26, 27] was employed when psychiatric syndromes were clinically obvious or suspected. Serology profiling for each patient was performed using standard immunoassays. Patients were assigned to the CNS or the non-CNS group according to the presence or absence of active CNS syndromes. The detailed diagnostic criteria for these groups are described below. Control sera were obtained from age- and sex-matched healthy donors and from patients with rheumatoid arthritis (RA), systemic sclerosis (SSc), SS, and multiple sclerosis (MS), all of which were diagnosed using standard criteria [28–31]. This study was approved by the Ethical Committee of our institution, and the principles of the Declaration of Helsinki were followed throughout the study.

### Diagnosis of CNS lupus

Final clinical diagnoses and classifications of the various NP syndromes for inclusion in the study were made by an experienced rheumatologist (MH) and psychiatrist (KN) according to the standardized ACR nomenclature and case definitions for NP lupus syndromes [2]. Although the ACR nomenclature and case definitions include 12 CNS and

seven peripheral nervous system syndromes [2, 26, 27], we used only the 12 CNS syndromes for the inclusion criteria for active CNS lupus because of the substantial differences between the central and peripheral nervous systems in anatomy, function, and clinical characteristics. Slight or mild cognitive dysfunction without significant clinical impairment, as indicated only by detailed neuropsychological testing (which was sometimes performed for another study), was excluded from the CNS syndromes used in our study. Tension headache and episodic tension-type headache were also excluded. CNS syndromes were further classified into neurologic disorders (aseptic meningitis, cerebrovascular disease, demyelinating syndrome, headache, movement disorders, myelopathy, and seizure disorders) and psychiatric disorders (acute confusional state, anxiety disorders, clinically evident cognitive dysfunction, mood disorders, and psychosis) [2].

#### Production of recombinant U1-70k protein

Recombinant U1-70k protein was produced in *Escherichia coli*, as previously described [11]. The purity of the recombinant protein was assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and its reactivity against autoantibodies was assessed by Western blot analysis using serum samples from SLE patients and controls, as described below.

#### Serum self-IgG reactivities against the recombinant U1-70k polypeptide by Western blot

Reactivities of serum IgG autoantibodies against the recombinant U1-70k polypeptide in serum samples from some of the SLE patients were examined by standard Western blot analysis, as described previously [11].

#### Quantification of autoantibodies against the recombinant U1-70k polypeptide in serum samples from patients and controls by enzyme-linked immunosorbent assay (ELISA)

Next, autoantibodies against the recombinant U1-70k polypeptide in serum samples from patients with SLE and other autoimmune diseases and from the normal healthy controls (NHCs) were quantified through solid-phase, direct ELISAs using the recombinant U1-70k polypeptide, as previously described [32] with slight modifications. Purified autoantigen [0.5 µg/ml in phosphate-buffered saline (PBS)] was coated onto the wells of a microtiter plate (Nunc, Roskilde, Denmark) through overnight incubation at 4 °C. The wells were then blocked for 2 h using 200 µl of PBS containing 1 % bovine serum albumin (BSA) at room temperature. After the plate was washed five times

with 400 µl of PBS containing 0.1 % Tween 20 (PBS-T), 100 µl of the diluted serum samples (1:200 in PBS-T containing 0.3 % BSA) were incubated at room temperature for 2 h. After the plate was washed, 100 µl of diluted horseradish-peroxidase-(HRP)-conjugated sheep anti-human IgG (1:20,000 in PBS-T containing 0.3 % BSA) was added to each well and incubated at room temperature for 1 h. After the plate was washed, 100 µl of substrate solution (0.04 % *o*-phenylenediamine dihydrochloride with 0.012 % H<sub>2</sub>O<sub>2</sub>) was added to each well and incubated at room temperature for 30 min. The reaction was stopped by the addition of 100 µl of 2 N H<sub>2</sub>SO<sub>4</sub>. The absorbance was measured at 492 nm using a microplate reader. Autoantibody titers were expressed as the mean optical density (OD) values of the triplicate wells. All samples were assayed at the same time with the same incubation and development time. In addition, we coated a few wells of each plate with nonspecific human IgG as controls to check the stability of assays across experiments so that data could be compared across experiments. Samples with positive results by ELISAs were double checked for their reactivities to the recombinant U1-70k polypeptide by Western blot. Nonspecific reactions in ELISAs were examined using a plate coated with 0.5 µg/ml BSA in PBS with the same method as above.

#### Quantification by ELISA of the anti-U1-RNP antibodies in serum samples from patients and controls

Levels of serum anti-U1-RNP antibodies were also determined by commercial ELISA kits using mixed antigens, including recombinant U1-70k polypeptide, A and C polypeptides, and in-vitro-transcribed U1 RNA, in addition to recombinant RNP (Mesacup<sup>®</sup> RNP-II test; Medical and Biological Laboratories, Nagoya, Aichi, Japan), according to the manufacturer's protocol [23, 33]. This ELISA kit has been shown to exhibit the same sensitivity and specificity for detecting anti-U1-RNP antibodies as the double immunodiffusion method [33]. The numbers of NHC samples examined varied among anti-U1-70k-antibody and anti-U1-RNP-antibody ELISAs because of sample and antigen availability.

#### Statistical analyses

Results of ELISAs were correlated with the final clinical diagnosis for each patient. Two-group comparisons were analyzed using Fisher's exact test for categorical variables and the Mann-Whitney *U* test for continuous variables. Three (or more) group comparisons were analyzed by the Kruskal-Wallis test, the Steel multiple comparison test, and the Steel-Dwass multiple comparison test for continuous variables. Relationships between antibody levels and

other continuous variables were analyzed using Spearman's rank correlation. Values of  $p < 0.05$  were considered statistically significant, and all tests were two tailed. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the antibodies were also calculated. All statistical analyses were performed using the JMP statistical software (version 9.0; SAS Institute, Cary, NC, USA).

## Results

### Clinical characteristics of SLE patients

Of the 106 patients with SLE enrolled in the study, 100 were women and six were men. Median patient age was 31 (range 16–68) years. Median disease duration after SLE diagnosis was 1 (range 0–20) years. Patients were all Japanese, except for a woman who was Chinese. The median score of Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)–Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [34] of the patients was 9.5 (range 0–31). Recently (i.e., within the previous month) diagnosed, active CNS syndromes were observed in 32 patients (CNS group), whereas the remaining 74 patients showed neither current CNS syndromes nor a history of CNS syndromes (non-CNS group). A neurologic disorder was diagnosed in 21 participants, a psychiatric disorder in 15, and both in four. The final clinical diagnoses and classifications of the various NP syndromes for inclusion in the study were made according to the standardized ACR nomenclature and case definitions for NP-SLE [2, 26, 27]. No significant differences in other clinical parameters, such as sex, age, and disease duration, were observed between the CNS and non-CNS groups ( $p = 0.78, 0.78, \text{ and } 0.68$ , respectively). Antiphospholipid antibodies have been the most widely investigated antibodies in NP-SLE, and there is abundant research on their association with focal (stroke, seizures, epilepsy, and migraine headaches) and diffuse neurological manifestations, including cognitive impairment [4]. However, we found no significant association between antiphospholipid antibodies and CNS syndromes, neurologic disorders, or psychiatric disorders among SLE patients ( $p = 0.79, 0.73, \text{ and } 0.76$ , respectively).

### Western blot analysis of serum self-IgG reactivities against recombinant U1-70k polypeptide

Reactivities of the serum IgG autoantibodies against recombinant U1-70k polypeptide in serum samples from some SLE patients in the CNS group ( $n = 27$ ) were investigated by Western blot analysis (Fig. 1a). The


positive samples all yielded positive ELISA results, and the samples generating negative results all produced negative ELISA results. In addition, we performed Western blot analysis for specificity controls using serum samples from the NHCs ( $n = 10$ ) and patients with RA ( $n = 12$ ), SSc ( $n = 11$ ), SS ( $n = 12$ ), and MS ( $n = 11$ ) and observed positive results, with a small percentage of patients with other diseases, as previously reported [20] (Fig. 1b–f, respectively).

Anti-U1-70k antibody titers as measured using ELISA were higher in patients with active SLE than in NHCs or patients with RA, SSc, SS, or MS

Serum samples from 106 SLE patients, including 32 with active CNS syndromes, and from 135 NHCs measured using anti-U1-70k-antibody ELISAs, and 28 NHCs using anti-U1-RNP-antibody ELISAs, were subjected to ELISA to quantify the autoantibodies reactive against these antigens. The original serum samples used in verifying the recombinant U1-70k polypeptide by Western blot analysis, as described above, were included in these final samples. OD values of SLE patient serum samples were significantly higher than those of NHCs in ELISAs performed using U1-70k and U1-RNP ( $p < 0.0001$  and  $p < 0.0001$ , respectively) (Figs. 2 and 3a, b). Samples with positive results by ELISA were also reconfirmed for their reactivities to the recombinant U1-70k polypeptide by Western blot. To assess disease specificity for SLE of anti-U1-70k antibodies, we also performed ELISAs using serum samples from patients with RA, SSc, SS, and MS. ELISA-generated U1-70k OD values for serum samples from SLE patients were significantly higher than those from patients with the other autoimmune diseases and from NHCs ( $p < 0.05$  for SLE vs. all of the other controls using the Steel multiple comparison test; Fig. 2). As summarized in Tables 1 and 2, anti-U1-70k antibodies were detected in serum samples of patients exhibiting various clinical manifestations of active SLE. Prevalence and titers of anti-U1-70k antibodies were not significantly associated with SLE-specific manifestations. There was no significant correlation between levels of serum anti-U1-70k antibodies and SELENA–SLEDAI scores ( $p = 0.19$  by Spearman's rank correlation). Established relationships, such as those with Raynaud's phenomenon, hand swelling, myositis, sclerodactyly, and pulmonary hypertension [16], were not assessed to avoid increasing the incidence of  $\alpha$  errors.

Comparisons of antibody titers against U1-70k and U1-RNP among CNS and non-CNS groups using ELISA

No OD values were significantly different between the SLE patients with and without active CNS syndromes in




**Fig. 1** Representative results of Western blot analysis of reactivities of serum immunoglobulin G (IgG) autoantibodies against the recombinant 70-kDa polypeptide of the U1-ribonucleoprotein (RNP) complex (U1-70k) in serum samples derived from a subset of systemic lupus erythematosus (SLE) patients from the central nervous system (CNS) group (a  $n = 27$ ). All positive samples yielded positive results in enzyme-linked immunosorbent assays (ELISAs), and all samples producing negative results in the Western blot analysis had negative results in ELISAs. *Anti-His* results for anti-His-

Tag antibodies that recognize His-Tags placed in the fusion recombinant proteins. *CNS-SLE* samples from SLE patients in the CNS group, who exhibited active CNS syndromes related to SLE. In addition, we performed Western blot analysis using serum samples from normal healthy controls (b  $n = 10$ ) and patients with rheumatoid arthritis (c  $n = 12$ ), systemic sclerosis (d  $n = 11$ ), Sjögren's syndrome (e  $n = 12$ ), and multiple sclerosis (f  $n = 11$ ) and observed positive results with a small percentage of patients with other diseases

ELISAs for the following autoantibodies: U1-70k ( $p = 0.83$ ) and U1-RNP ( $p = 0.96$ ) (Fig. 3a, b, respectively). However, when CNS groups with psychiatric disorders and with neurologic disorders were separately compared with SLE patients without those disorders, anti-

U1-70k antibody levels were significantly elevated in SLE patients with psychiatric disorders than levels in SLE patients without psychiatric disorders ( $p = 0.030$  by the Steel–Dwass multiple comparison test; Fig. 4a). By contrast, there was no significant difference in levels of serum

anti-U1-RNP antibodies in SLE patients with or without psychiatric syndromes ( $p = 0.555$ , Fig. 4b). In addition, there were no significant differences in the levels of serum anti-U1-70k antibodies or anti-U1-RNP antibodies in SLE patients with or without neurologic syndromes ( $p = 0.61$  and  $0.51$ , Fig. 5a, b, respectively). When samples from SLE patients with and without psychiatric syndromes were compared using a theoretical cutoff titer of 0.83 (OD) for anti-U1-70k antibodies as the NHC mean + 3 standard deviations (SD), sensitivity, specificity, PPV, and NPV determined for the diagnosis of psychiatric SLE were 67 %, 59 %, 21 %, and 92 %, respectively. In addition, the




**Fig. 2** Serum samples from 106 systemic lupus erythematosus (SLE) patients, including 32 with active central nervous system (CNS) syndromes, and 135 normal healthy controls (NHCs) were subjected to enzyme-linked immunosorbent assay (ELISA) to quantify the anti-70-kDa polypeptide of the U1-ribonucleoprotein (RNP) complex (U1-70k) antibodies (Abs). Optical density (OD) values of SLE patient serum samples were significantly higher than those of NHCs in the U1-70k ELISAs ( $p < 0.0001$ ). To assess disease specificity for SLE of the anti-U1-70k antibodies, we also performed ELISAs using serum samples from patients with rheumatoid arthritis (RA), systemic sclerosis (SSc), Sjögren's syndrome (SS), and multiple sclerosis (MS) ( $n = 20, 20, 20$ , and  $20$ , respectively). U1-70k ELISA OD values for serum samples from SLE patients were significantly higher than those from patients with the other diseases ( $p < 0.05$  for SLE vs. the other diseases using the Steel multiple comparison test)

prevalence of psychiatric SLE among samples with high titers of anti-U1-RNP antibodies in ELISA and of anti-U1-70k antibodies in ELISA was two times that of samples with high titers of anti-U1-RNP antibodies in ELISA but without anti-U1-70k antibodies in ELISA (21 % vs. 10 %, respectively), although this relationship did not reach statistical significance ( $p = 0.66$  by Fisher's exact test), probably due to the limited sample size. In addition, we found no significant difference in levels of serum anti-U1-70k antibodies in SLE patients with or without antiphospholipid antibodies or those with or without psychiatric syndromes ( $p = 0.34, 0.47$ , and  $0.23$ ).

## Discussion

Major findings of this study were the following: (1) no significant difference was observed in the levels of serum anti-U1-70k antibodies in SLE patients with or without CNS syndromes; (2) levels were significantly elevated in SLE patients with vs. those without psychiatric syndromes; and (3) no significant difference was observed in the levels of serum anti-U1-RNP antibodies in SLE patients with or without psychiatric syndromes. These observations indicate that anti-U1-70k but not anti-U1-RNP antibodies in serum might be involved in the pathological mechanisms of psychiatric syndromes, but not of whole CNS or neurologic syndromes, in patients with SLE.

Serum anti-U1-70k but not serum anti-U1-RNP antibody levels were significantly elevated in SLE patients compared with those without psychiatric syndromes. In addition, the prevalence of psychiatric SLE among samples with high titers of both anti-U1-RNP and anti-U1-70k antibodies measured with ELISAs was twice as high as those among samples with high titers of anti-U1-RNP antibodies but without anti-U1-70k antibodies, although this relationship did not reach statistical significance,



**Fig. 3** Comparisons of enzyme-linked immunosorbent assay (ELISA) autoantibody titers against 70-kDa polypeptide of the U1-ribonucleoprotein (RNP) complex (U1-70k) (a) and U1-ribonucleoprotein (RNP) (b) between the central nervous system (CNS) and non-CNS groups ( $n = 32$  and  $74$ , respectively) and between 135

NHCs with anti-U1-70k antibody ELISAs and 28 NHCs with anti-U1-RNP antibody ELISAs. No optical density (OD) values in ELISAs of these antibodies (Abs) differed significantly between SLE patients with and without active CNS syndromes ( $p = 0.83$  for U1-70k and  $p = 0.96$  for U1-RNP by the Steel-Dwass multiple comparison test)